Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Journal of gastroenterology

• Publication date

  2026-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00535-026-02347-yPMID 41620983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct comparison of mass cytometry and single-cell RNA sequencing of human peripheral blood mononuclear cells

  2024cited by this paper
• SeuratExtend: streamlining single-cell RNA-seq analysis through an integrated and intuitive framework

  2024cited by this paper
• Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study.

  2024cited by this paper
• Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment

  2023cited by this paper
• GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers

  2023cited by this paper
• FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction.

  2023cited by this paper
• The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer

  2023cited by this paper
• The Gene Ontology knowledgebase in 2023

  2023cited by this paper
• BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

  2022cited by this paper
• Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System

  2022cited by this paper
• Activated Natural Killer Cells-Dependent Dendritic Cells Recruitment and Maturation by Responsive Nanogels for Targeting Pancreatic Cancer Immunotherapy.

  2022cited by this paper
• Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients

  2022cited by this paper
• An Innovative Approach to Tissue Processing and Cell Sorting of Fixed Cells for Subsequent Single-Cell RNA Sequencing

  2022cited by this paper
• Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer.

  2022cited by this paper
• Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.

  2022cited by this paper
• Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment

  2022cited by this paper
• The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges

  2022cited by this paper
• Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment

  2022cited by this paper
• Cannabinoid Receptor Type-2 in B Cells Is Associated with Tumor Immunity in Melanoma

  2021cited by this paper
• Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

  2021cited by this paper
• First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

  2021cited by this paper
• Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer

  2021cited by this paper
• LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

  2021cited by this paper
• Correction to: HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFβ axis

  2021cited by this paper
• Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine

  2021cited by this paper
• Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

  2021cited by this paper
• Gene Set Knowledge Discovery with Enrichr

  2021cited by this paper
• Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma

  2020cited by this paper
• Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy

  2020cited by this paper
• IL-32γ potentiates tumor immunity in melanoma

  2020cited by this paper
• Inference and analysis of cell-cell communication using CellChat

  2020cited by this paper
• Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy.

  2020cited by this paper
• The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.

  2020cited by this paper
• Integrated analysis of multimodal single-cell data

  2020cited by this paper
• Determining cell-type abundance and expression from bulk tissues with digital cytometry

  2019cited by this paper
• Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells

  2019cited by this paper
• Fast, sensitive, and accurate integration of single cell data with Harmony

  2019cited by this paper
• Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage

  2018cited by this paper
• Human Bone Marrow Assessment by Single Cell RNA Sequencing, Mass Cytometry and Flow Cytometry

  2018cited by this paper
• FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

  2018cited by this paper
• Loss of natural killer T cells promotes pancreatic cancer in LSL‐KrasG12D/+ mice

  2017cited by this paper
• Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer

  2017cited by this paper
• Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma

  2016cited by this paper
• Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein: A Key Marker of Functional Regulatory T Cells

  2015cited by this paper
• Glucocorticoid-induced tumor necrosis factor receptor–related protein co-stimulation facilitates tumor regression by inducing IL-9–producing helper T cells

  2015cited by this paper
• Tumor necrosis factor receptor superfamily costimulation couples T cell receptor signal strength to thymic regulatory T cell differentiation

  2014cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

  2013cited by this paper
• GITR-Dependent Regulation of 4-1BB Expression: Implications for T Cell Memory and Anti–4-1BB–Induced Pathology

  2013cited by this paper
• GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability

  2013cited by this paper
• Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas

  2012cited by this paper
• Enhanced GITR/GITRL interactions augment IL‐27 expression and induce IL‐10‐producing Tr‐1 like cells

  2012cited by this paper
• The Role of XCR1 and its Ligand XCL1 in Antigen Cross-Presentation by Murine and Human Dendritic Cells

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• IL-15–Dependent Upregulation of GITR on CD8 Memory Phenotype T Cells in the Bone Marrow Relative to Spleen and Lymph Node Suggests the Bone Marrow as a Site of Superior Bioavailability of IL-15

  2012cited by this paper
• Significance of Lymph Node Micrometastasis in Pancreatic Cancer Patients

  2011cited by this paper
• CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

  2011cited by this paper
• Clinical Implications of Immunohistochemically Demonstrated Lymph Node Micrometastasis in Resectable Pancreatic Cancer

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection

  2010cited by this paper
• Surgical Implication of Micrometastasis for Pancreatic Cancer

  2010cited by this paper
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

  2010cited by this paper
• Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer.

  2010cited by this paper
• ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks

  2009cited by this paper
• Tumor-derived TGF-β Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas Cancer

  2009cited by this paper
• Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

  2008cited by this paper
• GITR/GITRL: More than an effector T cell co‐stimulatory system

  2007cited by this paper
• Glucocorticoid-Induced TNFR-Related Protein Lowers the Threshold of CD28 Costimulation in CD8+ T Cells1

  2007cited by this paper
• Tumor Necrosis Factor Receptor (TNFR)-associated Factor 5 Is a Critical Intermediate of Costimulatory Signaling Pathways Triggered by Glucocorticoid-induced TNFR in T Cells*

  2006cited by this paper
• Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations

  2004cited by this paper
• Cytoscape: a software environment for integrated models of biomolecular interaction networks.

  2003cited by this paper
• CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.

  2002cited by this paper
• Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance

  2002cited by this paper
• Gene Ontology: tool for the unification of biology

  2000cited by this paper
• Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.

  1999cited by this paper

• No citing papers are available for this paper.